Quick answer
EchoLaser treats the prostate with laser, carried by fine needles that go in through the perineum. Rezum uses water vapor, released by an instrument that goes in through the urethra.1 Both preserve ejaculation in most men.1,3 In the only randomized trial between them, with 80 men, symptoms improved more with EchoLaser at 6 months, and urine flow improved similarly.2 Rezum has longer follow-up in the studies.4 In my practice, both are done under local anesthesia with sedation. Rezum is done without a hospital stay, and EchoLaser with a short hospital admission: you arrive and go home the same day. The catheter stays for 5 to 7 days with Rezum and 7 days with EchoLaser.
How each one works
In EchoLaser, fine needles go in through the perineum, the area between the scrotum and the anus, guided by ultrasound. A fiber passes through each needle and releases the laser inside the prostate. The heat coagulates the tissue, and the prostate shrinks over the following months.1 The fibers are placed at a safe distance from the urethra and the bladder neck.15
In Rezum, an instrument goes in through the urethra, and a fine needle releases water vapor inside the prostate. Usually, each lateral lobe receives 1 to 3 injections, and the median lobe may receive 1 to 2. The heat destroys the cells of the treated tissue, and the body absorbs it over the following weeks.1
In both, the tissue is not removed on the spot. That is why improvement comes gradually, over a few months.4,15
Side by side
| Item | EchoLaser | Rezum |
|---|---|---|
| Route | Needles through the perineum | Instrument through the urethra |
| Energy | Laser | Water vapor |
| Anesthesia, in my practice | Local with sedation | Local with sedation |
| Hospital stay, in my practice | Short: you arrive and go home the same day | None |
| Catheter, in my practice | 7 days | 5 to 7 days |
| Loss of ejaculation, in one review | 5% | 3% |
| Longest randomized trial | 6 months, against Rezum | 5 years, against a sham procedure |
Loss of ejaculation comes from a review of 24 studies on the less invasive techniques.3 The randomized trials are the one that compared EchoLaser with Rezum2 and the one that compared Rezum with a sham procedure.4
What the studies show
I found only one randomized trial that compared the two techniques directly. It randomized 80 men in 2024. Both procedures were done under sedation, and all went home the same day except one, who needed bladder irrigation for longer. At 3 and 6 months, symptoms and quality of life improved more with EchoLaser, and quality of life improved faster. Urine flow and residual urine improved similarly. There were complications in 11 of the 80 men, and one of them was more serious, a prostate abscess.2
In the part of the same trial on sexual function, with 61 sexually active men, erections were stable in both groups at 6 months. In the EchoLaser group, they dipped slightly at 3 months and recovered by 6. The ejaculation score improved in both groups. Prostates were larger in the EchoLaser group, and at the last assessment no one was taking prostate medication.5
The trial is small, and follow-up is 6 months, as the authors themselves acknowledge.2 The European guideline calls for larger and longer randomized trials for both techniques.1
Outside that trial, each technique has its own figures. In the randomized Rezum trial against a sham procedure, symptoms remained 48% below the starting value at 5 years.4 For EchoLaser, a review of 17 studies, with 777 men, showed at 12 months an IPSS 12.6 points lower, urine flow 6.3 mL/s higher and a prostate 21 g smaller. The authors note that follow-up is still short and call for studies comparing EchoLaser with other techniques.8
Ejaculation and erections
In the European guideline, more than 85% of men kept their ejaculation after EchoLaser.1 Rezum tends to preserve ejaculation in 80% to 90% of cases.6,9 In a review that looked at both techniques, loss of ejaculation was 5% with EchoLaser and 3% with Rezum.3 These figures come from different studies.
For erections, the randomized trial found no difference between the two at 6 months.5 In the randomized Rezum trial, there was no new, lasting erectile dysfunction over 5 years.4 More detail is in ejaculation and erections after each technique.
Anesthesia, catheter and recovery
In my practice, EchoLaser and Rezum are done under local anesthesia with sedation. Rezum is done without a hospital stay: once it is over, you go home. EchoLaser is done with a short hospital admission: you arrive and go home the same day. The catheter stays for 5 to 7 days with Rezum and 7 days with EchoLaser, and is removed at my office. After it comes out, you can go back to work without physical effort and drive. The gym, strenuous effort and sex wait until after 30 days.
In the literature, most men had EchoLaser under local anesthesia and went home within 24 hours.1 In one of the first studies, with 21 men, the catheter stayed for 8.7 days on average.15 In the randomized trial between the two techniques, all went home the same day except one.2
Chance of retreatment
No study has compared the chance of retreatment between EchoLaser and Rezum. The figures below come from different studies.
With Rezum, repeat surgery was 4.4% at 5 years in the randomized trial.4 In health records of more than 420,000 procedures in the United States, retreatment at 5 years was 14%, without adjustment for prostate size.7 The European guideline cites 15.8% at 4 years, counting surgery and restarting medication.1 In a French real-world series, 23% needed retreatment within 2 years, with medication or surgery.9
For EchoLaser, follow-up is shorter. In a series of 40 men followed for a median of 57 months, the improvement held up to the last assessment.10 In prostates over 80 g, repeat surgery was more frequent, as the section below shows.
Large prostate and median lobe
The randomized Rezum trial included prostates of 30 to 80 g.4 In the European guideline, a review of prostates over 80 g, up to 150 g, led to a wider indication in some countries.1 The median lobe, the part of the prostate that grows into the bladder, can be treated with vapor. In a study from Chile, repeat surgery at about two and a half years was 3.2% without a median lobe and 21% when it protruded more than 1 cm into the bladder.14 The page Rezum for a large prostate has more detail.
The European guideline does not cite a prostate weight for EchoLaser.1 In an Italian series of 43 men with a prostate of 80 g or more (median 96 g), symptoms and urine flow improved at 12 months, and 9% needed another operation.11 In another, with 85 men with a prostate over 80 g, the catheter could not be removed on day 7 in 24.7% and on day 14 in 7.1%, and 12.9% later needed HoLEP, over a median follow-up of 18 months. The improvement in urine flow appeared mainly from 6 months onward.12 With a median lobe, in a series of 31 men, the IPSS fell from 22 to 6.5 at 6 months, and 9 of the 10 who depended on a catheter were able to urinate on their own again.13
These are single-center studies without a comparison group. In practice, this has to be assessed case by case. The page which technique for each prostate size compares the options.
How I approach it
I perform both techniques. I have performed EchoLaser since 2025, when the technique arrived in Brazil, and I did one of the first cases in the country. With Rezum, I was one of the pioneers in Brazil, with more than 100 cases among my own patients and proctoring.
Before recommending either, I assess the size and shape of the prostate, whether there is a median lobe, the symptoms and what the patient wants to preserve. I explain that with both, improvement comes gradually, and that EchoLaser still has shorter studies. I also present the operations that remove tissue, such as HoLEP, Greenlight and TURP, and the decision is made together with the patient.
When to see a urologist
- If you have an enlarged prostate and medication does not bring enough relief
- If preserving ejaculation weighs in your decision
- If you want to compare EchoLaser with Rezum or another technique
- If you have a large prostate or a median lobe and want to know your options
Send your case
If you would like to know, before a consultation, which technique makes sense for your case, fill in the form below. If you know it, tell me the prostate weight on ultrasound or MRI and the medications you take. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
EchoLaser or Rezum: which one is better?+
It depends on what matters most to you. In the only randomized trial between the two, with 80 men, symptoms and quality of life improved more with EchoLaser at 3 and 6 months, and urine flow improved similarly.2 That trial lasted only 6 months, and Rezum has a randomized trial with 5 years of follow-up.4 I assess both techniques with each patient.
What is the difference between EchoLaser and Rezum?+
In EchoLaser, fine needles go in through the perineum, guided by ultrasound, and carry laser fibers into the prostate. In Rezum, an instrument goes in through the urethra, and a fine needle releases water vapor inside the prostate. In both, heat treats the tissue, and the prostate shrinks gradually.1
Do both preserve ejaculation?+
In most men, yes. In a review of 24 studies, loss of ejaculation was 5% with EchoLaser and 3% with Rezum.3 In the randomized trial between the two, the ejaculation score improved in both groups, and erections were stable at 6 months.5
How long are the catheter and hospital stay with each one?+
In my practice, both are done under local anesthesia with sedation. Rezum is done without a hospital stay, and EchoLaser with a short hospital admission: you arrive and go home the same day. The catheter stays for 5 to 7 days with Rezum and 7 days with EchoLaser, and is removed at my office.
Which one is less likely to need retreatment?+
It is not yet possible to say. No study has compared this between the two. After Rezum, repeat surgery was 4.4% at 5 years in the randomized trial and 14% at 5 years in real-world data from the United States.4,7 For EchoLaser, most studies still have short follow-up.8
I have a large prostate or a median lobe. Does that change the choice?+
It may. With Rezum, the median lobe can be treated with vapor, but in one study repeat surgery was more common when it protruded more than 1 cm into the bladder.1,14 For EchoLaser, there are small series with prostates over 80 g and with a median lobe, without a comparison group.11,12,13 In practice, this has to be assessed case by case.
Who performs EchoLaser in São Paulo?+
I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I have performed EchoLaser since 2025, when the technique arrived in Brazil, and I did one of the first cases in the country. With Rezum, I was one of the pioneers in Brazil, with more than 100 cases among my own patients and proctoring. In my practice, both are done under local anesthesia with sedation. Rezum is done without a hospital stay, and EchoLaser with a short hospital admission: you arrive and go home the same day. The catheter stays for 5 to 7 days with Rezum and 7 days with EchoLaser. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU Guidelines on the Management of Non-neurogenic Male LUTS. European Association of Urology; 2026. Disease management chapter. EAU
- Pacini M, Zucchi A, Salonia A, et al. Short term results after minimally invasive treatments for benign prostatic enlargement: the first randomized trial comparing transperineal laser ablation and water vapor ablation. Prostate Cancer Prostatic Dis. 2025;28(4):978-984. PubMed
- Franco A, Ditonno F, Manfredi C, et al. Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction. Eur Urol. 2026;89(4):318-331. PubMed
- McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021;206(3):715-724. PubMed
- Zucchi A, Bartoletti R, Antonov P, et al. Preserving erectile and ejaculatory function in patients undergoing minimally invasive techniques: the first randomized clinical trial comparing convective water vapor ablation and transperineal laser ablation. J Sex Med. 2025;22(8):1447-1454. PubMed
- Destefanis P, Sibona M, Oderda M, et al. Ejaculation-sparing GreenLight anatomical PVP versus REZŪM for benign prostatic obstruction surgery with an ejaculation-sparing purpose: what are the early differences? Minim Invasive Ther Allied Technol. 2026;35(5):383-391. PubMed
- Carletti F, Tamborino F, Turcan A, et al. Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos. Eur Urol Focus. 2026;12(3):383-392. PubMed
- Pires IZ, Gobbo MODS, Fujimura AY, et al. Transperineal Laser Ablation for Treatment of Lower Urinary Tract Symptoms in Benign Prostate Enlargement: A Systematic Review and Meta-analysis. Int Braz J Urol. 2026;52(2):e20250423. PubMed
- Long Depaquit T, Berchiche W, Uleri A, et al. Two-Year Outcomes of Rezūm Therapy in Real-Life BPH Patients. Prostate. 2026;86(3):314-319. PubMed
- Patelli G, Altieri VM, Ierardi AM, et al. Transperineal Laser Ablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Long-Term Follow-Up in 40 Patients. J Vasc Interv Radiol. 2024;35(8):1187-1193. PubMed
- Polverino P, Moscardi L, Lo Re M, et al. Office-based transperineal laser ablation in patients with large prostates (≥80 mL): real-world evidence of safety and efficacy from a prospective single center cohort. Minerva Urol Nephrol. 2026. PubMed
- Conte FL, Saladino M, Lambertini L, et al. Safety and functional efficacy of transperineal laser ablation in large prostates (>80 mL): a prospective single-center study. Minerva Urol Nephrol. 2026;78(4):583-591. PubMed
- Ruffo A, Stanojevic N, Crocetto F, et al. Transperineal Laser Ablation of Symptomatic Benign Prostatic Hyperplasia With Median-Lobe Enlargement: A Single-Center Experience. Lasers Surg Med. 2026;58(7):524-531. PubMed
- Fulla J, Arroyave JS, Larenas F, et al. Impact of Median Lobe Protrusion on Outcomes of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: A Prospective Analysis. J Endourol. 2026;40(2):205-211. PubMed
- de Rienzo G, Lorusso A, Minafra P, et al. Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol. 2021;80(1):95-103. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
